News

According to the World Health Organization (WHO), chronic obstructive pulmonary disease (COPD) is the third leading cause of ...
Dupilumab reduces COPD exacerbations and Type 2 inflammation biomarkers, with strongest benefit in patients with high ...
Synchrony Medical announced that it received FDA 510 (k) clearance for its LibAirty airway clearance system.
Frequent consumption of a common drug that acts on the nervous system and treats a range of ailments may lead to faster ...
A key patent for Merck’s blockbuster drug Keytruda will expire in 2028. The cancer therapy brought the company $29.5 billion last year. Keytruda may also face “ price setting ” from the Inflation ...
A successful claim for PIP or ADP is worth between £29.20 and £187.45 each week in additional financial support and as the benefit is paid every four weeks, this amounts to between £116.80 and £749.80 ...
Those battling severe asthma, upper respiratory tract diseases, Chronic Obstructive Pulmonary Disease (COPD), Asbestosis and ...
Pulmonary arterial hypertension (PAH) is a rare, progressive disorder impacting small pulmonary arteries, leading to increased vascular resistance and heart failure. The latest report forecasts ...
This acquisition of Verona Pharma reflects the commitment we have to delivering innovative treatments to patients and our ...
Increasing prevalence of COPD and other respiratory illnesses across hospitals and home care settings is driving the demand ...
“The brain is the gatekeeper of longevity,” said Wyss-Coray. “If you’ve got an old brain, you have an increased likelihood of ...
Gabapentin is approved for seizures and post-herpetic neuralgia; gabapentin enacarbil is approved for restless legs syndrome.